{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:58:08Z","timestamp":1776779888048,"version":"3.51.2"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) is a rare and aggressive malignancy, accounting for only 5\u201310% of all urothelial carcinomas (UCs). Lung, bone, liver, and distant lymph nodes are common sites of metastasis, while gastrointestinal metastasis is extremely rare. We present a case of a 63-year-old female who developed a descending colon lesion 19 months after left radical nephroureterectomy for high-grade ureteral UC. The diagnosis was established by computed tomography (CT), magnetic resonance imaging (MRI), colonoscopy, and biopsy, which excluded primary colorectal malignancy. First-line therapy consisted of six 21-day cycles of gemcitabine plus cisplatin, followed by two cycles of tislelizumab maintenance immunotherapy. Restaging with contrast-enhanced CT and positron emission tomography\/computed tomography (PET\/CT) demonstrated disease progression. Despite switching to second-line nab-paclitaxel, the patient rapidly deteriorated from tumor cachexia and ultimately succumbed to septic shock secondary to severe pulmonary infection. This represents the first reported case of descending colon metastasis from primary ureteral UC. It highlights the colon as a potential metastatic site where biopsy is essential for definitive diagnosis. Notably, although the patient initially responded to platinum-based therapy, the subsequent rapid progression underscores the need for vigilant monitoring and timely adjustment of therapeutic strategies in managing such high-risk presentations.<\/jats:p>","DOI":"10.3390\/curroncol33040235","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:42:45Z","timestamp":1776771765000},"page":"235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Descending Colon Metastasis Following Radical Nephroureterectomy for Left Ureteral Carcinoma: A Case Report and Literature Review"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2636-9641","authenticated-orcid":false,"given":"Huaiwen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peizhe","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyao","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongji","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","volume":"84","author":"Seisen","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bignante, G., Manfredi, C., Lasorsa, F., Orsini, A., Licari, L.C., Bologna, E., Roadman, D.F., Amparore, D., Lucarelli, G., and Schips, L. (2024). Incidence, Timing, and Pattern of Atypical Recurrence after Minimally Invasive Surgery for Urothelial Carcinoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13123537"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update","volume":"87","author":"Birtle","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"306.e9","DOI":"10.1016\/j.urolonc.2018.02.009","article-title":"Upper Tract Urothelial Carcinoma Following Intravesical Bacillus Calmette-Gu\u00e9rin Therapy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Retrospective Study","volume":"36","author":"Nishiyama","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11864-019-0637-2","article-title":"Optimal Management of Upper Tract Urothelial Carcinoma: An Unmet Need","volume":"20","author":"Azizi","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hu, X.-H., Miao, J., Qian, L., Zhang, D.-H., and Wei, H.-B. (2022). The Predictors and Surgical Outcomes of Different Distant Metastases Patterns in Upper Tract Urothelial Carcinoma: A SEER-Based Study. Front. Surg., 9.","DOI":"10.3389\/fsurg.2022.1045831"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1245\/s10434-013-3349-z","article-title":"Metastatic Behavior of Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy: Association with Primary Tumor Location","volume":"21","author":"Tanaka","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s11255-013-0514-z","article-title":"Segmental Ureterectomy Does Not Compromise the Oncologic Outcome Compared with Nephroureterectomy for Pure Ureter Cancer","volume":"46","author":"Hung","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ren, S., Feng, H., Bao, Y., Wei, Y., Ou, Y., Wang, Y., Lv, Q., Zhong, S., Zhou, F., and Fan, S. (2021). Ureteral Urothelial Carcinoma with Squamous Cell Carcinoma and Sarcomatoid Carcinoma Differentiation: A Case Report. BMC Surg., 21.","DOI":"10.1186\/s12893-021-01099-1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/OTT.S230040","article-title":"Testicular Metastasis from Urothelial Carcinoma of the Renal Pelvis: A Rare Case and Review of the Literature","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5348\/100135Z12TY2024CR","article-title":"Massive Renal Pelvis Urothelial Carcinoma with Invasion of the Descending Colon and Cutaneous Metastases: A Case Report and Literature Review","volume":"10","author":"Yang","year":"2024","journal-title":"J. Case Rep. Images Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e942864-1","DOI":"10.12659\/AJCR.942864","article-title":"Cardiac and Intramuscular Metastases Following Nephroureterectomy for Metachronous Urothelial Carcinoma","volume":"25","author":"Chan","year":"2024","journal-title":"Am. J. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.14740\/jmc4201","article-title":"Upper Tract Urothelial Carcinoma Complicated by Skeletal Muscle Metastases","volume":"15","author":"Friesen","year":"2024","journal-title":"J. Med. Cases"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e42268","DOI":"10.1097\/MD.0000000000042268","article-title":"Choroidal Metastasis as the First Manifestation of Renal Pelvis Carcinoma: A Case Report","volume":"104","author":"Che","year":"2025","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.euros.2022.04.005","article-title":"Outcomes for Atypical Tumor Recurrences Following Minimally Invasive Kidney Cancer Operations","volume":"40","author":"Russo","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2026.02.002","article-title":"Divergent Differentiation and Histologic Subtypes in Upper Tract Urothelial Carcinoma Demonstrate Distinct Patterns of Extraurothelial Recurrence","volume":"86","author":"Wang","year":"2026","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","article-title":"Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis","volume":"203","author":"Mori","year":"2020","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.humpath.2014.04.015","article-title":"The Utility of P63, P40, and GATA-Binding Protein 3 Immunohistochemistry in Diagnosing Micropapillary Urothelial Carcinoma","volume":"45","author":"Lin","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40364-021-00260-5","article-title":"P63 Expression in Human Tumors and Normal Tissues: A Tissue Microarray Study on 10,200 Tumors","volume":"9","author":"Steurer","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1054\/cdip.2001.0063","article-title":"Application of Cytokeratin 7 and 20 Immunohistochemistry to Diagnostic Pathology","volume":"7","author":"Campbell","year":"2001","journal-title":"Curr. Diagn. Pathol."},{"key":"ref_22","first-page":"99","article-title":"Coordinate Expression of Cytokeratin-7 and Cytokeratin-20 Defines Unique Subsets of Carcinomas","volume":"3","author":"Wang","year":"1995","journal-title":"Appl. Immunohistochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/modpathol.2008.117","article-title":"Differential Diagnostic and Functional Role of the Multi-Marker Phenotype CDX2\/CK20\/CK7 in Colorectal Cancer Stratified by Mismatch Repair Status","volume":"21","author":"Lugli","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0959-8049(02)00008-4","article-title":"Cytokeratins 20 and 7 as Biomarkers","volume":"38","author":"Tot","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/npmj.npmj_297_24","article-title":"A Study of Immunohistochemical Expression of P63 in Colorectal Carcinoma","volume":"32","author":"Nair","year":"2025","journal-title":"Niger. Postgrad. Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO Classification of Tumours of the Digestive System","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.5858\/arpa.2014-0061-RA","article-title":"Immunohistochemistry in Undifferentiated Neoplasm\/Tumor of Uncertain Origin","volume":"138","author":"Lin","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, plus Cisplatin in Patients with Bladder Cancer","volume":"23","author":"Sengelov","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients with High-Grade Upper Tract Urothelial Carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., and Yu, L. (2020). The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00343"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Skowron, M.A., Melnikova, M., van Roermund, J.G.H., Romano, A., Albers, P., Thomale, J., Schulz, W.A., Niegisch, G., and Hoffmann, M.J. (2018). Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020590"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/03915603221139907","article-title":"Management of Metastatic Urothelial Carcinoma: Current Approach, Emerging Agents, and Future Perspectives","volume":"90","author":"Iacovelli","year":"2023","journal-title":"Urologia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline Interim Update on First-Line Therapy in Advanced Urothelial Carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-Label, Randomized Phase III Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (La\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12967-025-06237-4","article-title":"The Effectiveness and Safety of RC48 Alone or in Combination with PD-1 Inhibitors for Locally Advanced or Metastatic Urothelial Carcinoma: A Multicenter, Real-World Study","volume":"23","author":"Ge","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-World Effectiveness and Safety of RC48-ADC Alone or in Combination with PD-1 Inhibitors for Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Multicenter, Retrospective Clinical Study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR Inhibition in Urothelial Carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102376","DOI":"10.1016\/j.clgc.2025.102376","article-title":"Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-Programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study","volume":"23","author":"Matsubara","year":"2025","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:54:32Z","timestamp":1776776072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040235"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040235","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}